FINWIRES · TerminalLIVE
FINWIRES

KKR Fundraising Cycle Expected to Last Through 2027, RBC Says

By

-- KKR (KKR) is positioned to benefit from a "K-shaped" bifurcation in the alternative asset management industry, where larger diversified managers are gaining share, supported by a fundraising supercycle expected to extend through 2027, RBC Capital Markets said.

Management said macro volatility could make its $7 per share guidance difficult to achieve, particularly as exits are delayed. However, RBC said in a Tuesday note that its estimates and consensus already reflected a lower baseline of about $6 per share heading into the quarter, helping reset expectations positively.

The firm said KKR is benefiting from a fundraising supercycle driven by a secular shift in which limited partners are consolidating relationships with fewer general partners. This dynamic is reinforcing a "K-shaped" industry structure that favors large, diversified alternative asset managers.

RBC also highlighted KKR's portfolio company employee ownership program, noting a strong outcome from the sale of CoolIT at a 15x exit multiple. The firm said the program, now implemented across 85 portfolio companies, has supported higher employee retention, stronger revenue growth, and margin expansion.

The firm maintained an outperform rating on KKR and lowered its price target to $128 from $132.

Price: $101.08, Change: $-0.92, Percent Change: -0.91%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL